| Symbol | CRMD |
|---|---|
| Name | CORMEDIX INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 300 CONNELL DRIVE,SUITE 4200, BERKELEY HEIGHTS, New Jersey, 07922, United States |
| Telephone | +1 908 517-9500 |
| Fax | — |
| — | |
| Website | https://www.cormedix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001410098 |
| Description | Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs. Additional info from NASDAQ: |
Blum Susan 🔴 sold 8.4K shares of CorMedix Inc. (CRMD) at $8.30 Transaction Date: Aug 29, 2026 | Filing ID: 096386
Read moreHurlburt Elizabeth 🔴 sold 8.1K shares of CorMedix Inc. (CRMD) at $8.30 Transaction Date: Aug 29, 2026 | Filing ID: 096385
Read moreZelnick Kaufman Beth 🔴 sold 8.4K shares of CorMedix Inc. (CRMD) at $8.30 Transaction Date: Aug 29, 2026 | Filing ID: 096383
Read moreCorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
Read moreCormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreCorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
Read moreNew Form S-8 POS - CorMedix Inc. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001410098-26-000032 <b>Size:</b> 23 KB
Read more